Clinical Trials Directory

Trials / Conditions / Recurrent Lymphoma

Recurrent Lymphoma

15 registered clinical trials studyying Recurrent Lymphoma — 4 currently recruiting.

StatusTrialSponsorPhase
RecruitingCollecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
NCT05663502
AIDS Malignancy Consortium—
RecruitingCBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
NCT04870944
Children's Oncology GroupPhase 1 / Phase 2
Active Not RecruitingElimusertib for the Treatment of Relapsed or Refractory Solid Tumors
NCT05071209
National Cancer Institute (NCI)Phase 1 / Phase 2
Active Not RecruitingFrequency of Cachexia in Ambulatory Cancer Patients and Psychological Burden in Patients and Their Primary Car
NCT04090619
M.D. Anderson Cancer Center—
Active Not RecruitingSelpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating
NCT04320888
National Cancer Institute (NCI)Phase 2
WithdrawnTesting the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and You
NCT04500548
National Cancer Institute (NCI)Phase 1
RecruitingAscorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomo
NCT03418038
Mayo ClinicPhase 2
CompletedPevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or L
NCT03323034
Children's Oncology GroupPhase 1
CompletedIACS-010759 in Advanced Cancers
NCT03291938
M.D. Anderson Cancer CenterPhase 1
CompletedTrigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malig
NCT03229278
Rutgers, The State University of New JerseyPhase 1
CompletedEntinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
NCT02780804
National Cancer Institute (NCI)Phase 1
CompletedSelinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
NCT02323880
Children's Oncology GroupPhase 1
Active Not RecruitingTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph
NCT02465060
National Cancer Institute (NCI)Phase 2
CompletedVinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CN
NCT02343718
Canadian Cancer Trials GroupPhase 1
RecruitingEffects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Canc
NCT01790152
Children's Oncology Group—